NCT04670432View on ClinicalTrials.gov

Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 8, 2020

Primary Completion Date

November 28, 2023

Study Completion Date

November 28, 2023

Conditions

Deep Vein Thrombosis

Interventions

DRUG

Hydroxyethylrutoside

500 mg film-coated tablet

Trial Locations (1)

6229 HX

Maastricht University Medical Center, Maastricht

All Listed Sponsors

collaborator

Netherlands Thrombosis Foundation

UNKNOWN

lead

Maastricht University Medical Center

OTHER

NCT04670432 - Resolution Enhancement by a Supplemental Obstruction Lessening Venoactive Drug for Eight Weeks in Deep Vein Thrombosis | Biotech Hunter | Biotech Hunter